Toll Free: 1-888-928-9744

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 83 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H2 2016', provides in depth analysis on Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted pipeline therapeutics. 

The report provides comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) 
- The report reviews Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) Overview 8 Therapeutics Development 9 Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Products under Development by Stage of Development 9 Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Products under Development by Therapy Area 10 Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Products under Development by Indication 11 Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Products Glance 13 Late Stage Products 13 Early Stage Products 14 Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Products under Development by Companies 15 Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Products under Development by Universities/Institutes 18 Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Therapeutics Assessment 20 Assessment by Monotherapy/Combination Products 20 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Companies Involved in Therapeutics Development 27 Bionomics Limited 27 Catalyst Biosciences, Inc. 28 CoMentis, Inc. 29 Johnson & Johnson 30 Merck & Co., Inc. 31 NeuroDerm Ltd. 32 Saniona AB 33 SK Biopharmaceuticals Co., Ltd. 34 Sunovion Pharmaceuticals Inc. 35 Vanda Pharmaceuticals Inc. 36 Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Drug Profiles 37 (nicotine + opipramol hydrochloride) - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 AN-761 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 AQW-051 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 AVL-3288 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 AVL-8168 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 BNC-210 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 BNC-375 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 DSP-3748 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 Gln-1062 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 GTS-21 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 JNJ-39393406 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 NBP-14 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 SKLA-4R - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 Small Molecules to Agonize Alpha-7 Nicotinic Acetylcholine Receptor for Alzheimer's Disease and Schizophrenia - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 Small Molecules to Agonize CHRNA7 for Central Nervous System - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 Synthetic Peptide to Activate Neuronal Acetylcholine Receptor Subunit Alpha-7 for Alzheimer's Disease - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 TC-7020 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Dormant Projects 63 Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Discontinued Products 67 Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Featured News & Press Releases 68 Sep 21, 2016: Bionomics Announces Positive Results from Phase 2 Trial of BNC210 in Generalized Anxiety Disorder 68 Sep 16, 2016: Bionomics to present anti-anxiety drug treatment trial results and ADHD treatment research at ECNP 69 Jun 30, 2016: Bionomics To Trial Drug Against Post-Traumatic Stress Disorder 70 Jun 24, 2016: Enrolment Completed in BNC210 Generalised Anxiety Disorder Trial 70 Dec 08, 2015: Post Traumatic Stress Disorder Identified as Major New Market Opportunity for BNC210 71 Sep 16, 2015: Bionomics Reports Positive Data from Phase 1 Multiple Ascending Dose Trial of BNC210 for Anxiety and Depression 72 Apr 20, 2015: Bionomics Initiates Phase II Clinical Trial Of BNC210 For Treatment Of Anxiety 73 Feb 02, 2015: Bionomics Begins Phase 1b Study With Anxiety Drug Bnc210 74 Nov 17, 2014: Bionomics to Present BNC210 at Society for Neuroscience Meeting 74 Nov 11, 2014: Bionomics to Progress BNC210 in Clinical Trials 75 Sep 09, 2014: Positive Phase 1a Outcome for Memogain 77 Feb 21, 2014: Neurodyn creates Memogain Advisory Board 77 Jan 13, 2014: Neurodyn completes Part I of Memogain Phase IA Clinical Trial 78 Sep 27, 2013: Bionomics To Present BNC-375 At COGNITO Neuroscience Meeting 80 Apr 17, 2013: SK Biopharma Announces FDA's Authorization Of IND For SKL15508 For Treatment Of Cognitive Impairment Associated With Schizophrenia 81 Appendix 82 Methodology 82 Coverage 82 Secondary Research 82 Primary Research 82 Expert Panel Validation 82 Contact Us 82 Disclaimer 83
List of Tables
Number of Products under Development for, H2 2016 9 Number of Products under Development by Therapy Area, H2 2016 10 Number of Products under Development by Indication, H2 2016 11 Comparative Analysis by Late Stage Development, H2 2016 13 Comparative Analysis by Early Stage Products, H2 2016 14 Number of Products under Development by Companies, H2 2016 15 Products under Development by Companies, H2 2016 16 Products under Development by Companies, H2 2016 (Contd..1) 17 Number of Products under Investigation by Universities/Institutes, H2 2016 18 Products under Investigation by Universities/Institutes, H2 2016 19 Assessment by Monotherapy/Combination Products, H2 2016 20 Number of Products by Stage and Mechanism of Action, H2 2016 22 Number of Products by Stage and Route of Administration, H2 2016 24 Number of Products by Stage and Molecule Type, H2 2016 26 Pipeline by Bionomics Limited, H2 2016 27 Pipeline by Catalyst Biosciences, Inc., H2 2016 28 Pipeline by CoMentis, Inc., H2 2016 29 Pipeline by Johnson & Johnson, H2 2016 30 Pipeline by Merck & Co., Inc., H2 2016 31 Pipeline by NeuroDerm Ltd., H2 2016 32 Pipeline by Saniona AB, H2 2016 33 Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016 34 Pipeline by Sunovion Pharmaceuticals Inc., H2 2016 35 Pipeline by Vanda Pharmaceuticals Inc., H2 2016 36 Dormant Projects, H2 2016 63 Dormant Projects (Contd..1), H2 2016 64 Dormant Projects (Contd..2), H2 2016 65 Dormant Projects (Contd..3), H2 2016 66 Discontinued Products, H2 2016 67



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $3500
Multi User - US $7000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify